| Study to Investigate DRP-104 in Adults With Advanced Solid Tumors (NCT04471415) | Dracen Pharmaceuticals, Inc. | 2020-08-31 |
| Niraparib and Neratinib in Advanced Solid Tumors With Expansion Cohort in Advanced Ovarian Cancer (NCT04502602) | Virginia Commonwealth University | 2020-08-24 |
| A Safety Study of YQ23 in Advanced Solid Tumors Patients (NCT04513067) | New Beta Innovation Limited | 2020-08-21 |
| A Study of NM21-1480 in Adult Patients With Advanced Solid Tumors (NCT04442126) | Numab Therapeutics AG | 2020-08-19 |
| First-In-Human Dose-Escalation Study of STP1002 in Patients With Advanced-Stage Solid Tumors (NCT04505839) | ST Pharm Co., Ltd. | 2020-07-30 |
| Study of RP-3500, Camonsertib, in Advanced Solid Tumors (NCT04497116) | Repare Therapeutics | 2020-07-22 |
| A Phase I Study of QL1604 for Advanced Solid Tumors (NCT05801094) | Qilu Pharmaceutical Co., Ltd. | 2020-07-20 |
| Study BT8009-100 in Subjects With Nectin-4 Expressing Advanced Malignancies (NCT04561362) | BicycleTx Limited | 2020-07-17 |
| Study of Anti-PD-1 Antibody Multimodal Combination as First-line Treatment on Time Window of Advanced Solid Tumor (NCT04282278) | Hebei Medical University Fourth Hospital | 2020-07-16 |
| Study of BMS-986315 Alone and in Combination With Nivolumab or Cetuximab in Participants With Advanced Solid Tumors (NCT04349267) | Bristol-Myers Squibb | 2020-07-14 |
| Phase 1 Study of Oral TP-1454 (NCT04328740) | Sumitomo Pharma America, Inc. | 2020-07-08 |
| A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Preliminary Efficacy of CN1 (NCT04418141) | Curon Biopharmaceutical (Australia) Co Pty Ltd | 2020-07-02 |
| Safety and Early Signs of Efficacy of IL12-L19L19. (NCT04471987) | Philogen S.p.A. | 2020-07-01 |
| Phase 1/2 Study of APR-246 in Combination With Pembrolizumab in Subjects With Solid Tumor Malignancies (NCT04383938) | Aprea Therapeutics | 2020-06-25 |
| NBE-002 in Patients With Advanced Solid Tumors (NCT04441099) | NBE-Therapeutics AG | 2020-06-19 |
| Safety and Tolerability of ABM-1310 in Patients With Advanced Solid Tumors (NCT04190628) | ABM Therapeutics Corporation | 2020-06-16 |
| A Study of BPI-1178 in Patients With Advanced Solid Tumor and HR+/HER2- Breast Cancer (NCT04282031) | Beta Pharma (Suzhou) Co., Ltd. | 2020-06-15 |
| A Phase I Trial of Simmitinib in Advanced Solid Tumors (NCT04058587) | CSPC ZhongQi Pharmaceutical Technology Co., Ltd. | 2020-06-08 |
| PTX-35 in Patients With Advanced Solid Tumors (NCT04430348) | Pelican Therapeutics, Inc. | 2020-06-04 |
| An Open-label Study of ALPN-202 in Subjects With Advanced Malignancies (NCT04186637) | Alpine Immune Sciences, Inc. | 2020-06-02 |
| Study of ONCR-177 Alone and in Combination With PD-1 Blockade in Adult Subjects With Advanced and/or Refractory Cutaneous, Subcutaneous or Metastatic Nodal Solid Tumors or With Liver Metastases of Solid Tumors (NCT04348916) | Oncorus, Inc. | 2020-05-20 |
| AIMS Cancer Outcomes Study (NCT04495790) | Advanced Integrative Medical Science Institute | 2020-05-18 |
| A Study to Investigate Safety and Tolerability of SH3051 Capsule in Patients With Advanced Solid Tumors (NCT04423380) | Nanjing Sanhome Pharmaceutical, Co., Ltd. | 2020-05-14 |
| A Phase I/II Study of TJ004309 for Advanced Solid Tumor (NCT04322006) | TJ Biopharma Co., Ltd. | 2020-05-09 |
| Study of BGB-10188 as Monotherapy, and in Combination With Zanubrutinib, and Tislelizumab (NCT04282018) | BeiGene | 2020-04-29 |
| Safety, Tolerability and Pharmacokinetics of a Recombinant Humanized mAb Specific to B-and T-Lymphocyte Attenuator (BTLA) for Injection in Subjects With Advanced Malignancies (NCT04278859) | Shanghai Junshi Bioscience Co., Ltd. | 2020-04-28 |
| A Phase 1 Study of CX1003 (Kanitinib) in Patients with Advanced Solid Tumors (NCT04093466) | Beijing Konruns Pharmaceutical Co., Ltd. | 2020-04-27 |
| ATG-008 Combined With Toripalimab in Advanced Solid Tumors (NCT04337463) | Sichuan University | 2020-04-23 |
| Study of CHS-388 (Formerly Known as SRF388) in Patients With Advanced Solid Tumors (NCT04374877) | Coherus Oncology, Inc. | 2020-04-22 |
| A Study of T3011 Administered Via Intratumoral Injection in Patients With Advanced Solid Tumors (NCT05602792) | ImmVira Pharma Co. Ltd | 2020-04-21 |
| A Study to Assess YH001 in Combination With Toripalimab Injection in Subjects With Advanced Solid Tumors (NCT04357756) | Eucure (Beijing) Biopharma Co., Ltd | 2020-04-21 |
| Dose-escalation Study of APG-1387 and Toripalimab in Solid Tumors (NCT04284488) | Ascentage Pharma Group Inc. | 2020-04-10 |
| Study to Assess AFM24 in Advanced Solid Cancers (NCT04259450) | Affimed GmbH | 2020-04-07 |
| A Study of MSB0254 Injection in Advanced Solid Tumors (NCT04381325) | Suzhou Transcenta Therapeutics Co., Ltd. | 2020-04-01 |
| A Trial of SHR-1701 in Subjects With Advanced Solid Tumors (NCT04324814) | Atridia Pty Ltd. | 2020-03-31 |
| Study of SRF617 in Patients With Advanced Solid Tumors (NCT04336098) | Coherus Oncology, Inc. | 2020-03-16 |
| A Pharmacokinetic Interaction Study Between Apatinib Mesylate and Transporter Pgp Substrate Digoxin in Advanced Solid Tumor Subjects (NCT04322552) | Jiangsu HengRui Medicine Co., Ltd. | 2020-03-12 |
| A Study of SY 5609, a Selective CDK7 Inhibitor, in Advanced Solid Tumors (NCT04247126) | Syros Pharmaceuticals | 2020-01-23 |
| A Study of CS3005 in Advanced Solid Tumors (NCT04233060) | CStone Pharmaceuticals | 2020-01-10 |
| A Study of CS3002 in Subjects With Advanced Solid Tumors (NCT04162301) | CStone Pharmaceuticals | 2019-12-30 |
| A Phase I Study of CS1002 in Subjects With Advanced Solid Tumors (NCT04338724) | CStone Pharmaceuticals | 2019-12-27 |
| A Phase 1a/b Study of IK-175 as a Single Agent and in Combination With Nivolumab in Patients With Locally Advanced or Metastatic Solid Tumors and Urothelial Carcinoma (NCT04200963) | Ikena Oncology | 2019-12-18 |
| A Study in Subjects With Advanced Solid Tumors (NCT04156100) | Agenus Inc. | 2019-12-10 |
| Study of TPX-0046, A RET/SRC Inhibitor in Adult Subjects With Advanced Solid Tumors Harboring RET Fusions or Mutations (NCT04161391) | Turning Point Therapeutics, Inc. | 2019-12-06 |
| A Study of LY3499446 in Participants With Advanced Solid Tumors With KRAS G12C Mutation (NCT04165031) | Eli Lilly and Company | 2019-11-28 |
| A Phase Ia/Ib Study of IBI315 in Patients With HER2-expressing Advanced Solid Tumor (NCT04162327) | Innovent Biologics (Suzhou) Co. Ltd. | 2019-11-26 |
| A Study of Erdafitinib in Participants With Advanced Solid Tumors and Fibroblast Growth Factor Receptor (FGFR) Gene Alterations (NCT04083976) | Janssen Research & Development, LLC | 2019-11-20 |
| A Study of PRT811 in Participants With Advanced Solid Tumors, CNS Lymphoma and Gliomas (NCT04089449) | Prelude Therapeutics | 2019-11-06 |
| Study of Ifinatamab Deruxtecan (DS-7300a, I-DXd) in Participants With Advanced Solid Malignant Tumors (NCT04145622) | Daiichi Sankyo | 2019-11-03 |
| A Phase 1 Study of HS130 in Combination With Viagenpumatucel-L (HS110) in Patients With Solid Tumors (NCT04116710) | Heat Biologics | 2019-10-18 |
| A Study Evaluating the Safety, Tolerance and Anti-tumor Activity of a Study Drug in Subjects With Advanced Solid Tumors (NCT04135261) | Harbour BioMed US, Inc. | 2019-09-24 |
| A Study of Tulmimetostat DZR123 (CPI-0209) in Patients With Advanced Solid Tumors and Lymphomas (NCT04104776) | Novartis Pharmaceuticals | 2019-09-18 |
| Effect of Omeprazole on PK of Fluzoparib in Healthy Male Subjects (NCT04108676) | Jiangsu HengRui Medicine Co., Ltd. | 2019-09-07 |
| Study of TPX-0022 in Patients With Advanced NSCLC, Gastric Cancer or Solid Tumors Harboring Genetic Alterations in MET (NCT03993873) | Turning Point Therapeutics, Inc. | 2019-09-05 |
| A Phase Ib Study of HX008 in Patients With Advanced Solid Tumors (NCT04825392) | Taizhou Hanzhong biomedical co. LTD | 2019-09-05 |
| Study to Investigate the Safety, Blood Levels and Activity of MP0310 in Patients With Advanced Solid Tumors (NCT04049903) | Molecular Partners AG | 2019-09-02 |
| A Study of GFH018 in Patients With Advanced Solid Tumors (NCT05051241) | Zhejiang Genfleet Therapeutics Co., Ltd. | 2019-08-30 |
| A Phase I Study of YY-20394 in Patients With Advanced Solid Tumors (NCT04049929) | Shanghai YingLi Pharmaceutical Co. Ltd. | 2019-08-01 |
| A Study to Evaluate Lucitanib in Combination With Nivolumab in Patients With a Solid Tumor (NCT04042116) | Clovis Oncology, Inc. | 2019-07-29 |
| Safety of SNK01 in Subjects With Pathologically Confirmed Metastatic and/or Unresectable Cancer Refractory to Conventional Therapy (NCT03941262) | NKGen Biotech, Inc. | 2019-07-15 |
| Study of CPI-200 in Patients With Advanced Tumors (NCT03953742) | Coordination Pharmaceuticals, Inc. | 2019-07-01 |
| Anlotinib in Advanced Solid Tumors With FGFR Alteration (NCT03929965) | Shanghai Changzheng Hospital | 2019-07-01 |
| A Study of HS-10342 in Patients With Advanced Solid Tumor (NCT04060511) | Jiangsu Hansoh Pharmaceutical Co., Ltd. | 2019-06-19 |
| The Safety, Tolerability, and Initial Efficacy of HX009 in Patients With Advanced Malignancies (NCT04097769) | Waterstone Hanxbio Pty Ltd | 2019-06-12 |
| Long-term, Non-interventional, Observational Study Following Treatment With Fate Therapeutics FT500 Cellular Immunotherapy (NCT04106167) | Fate Therapeutics | 2019-06-11 |
| Phase IB Metformin, Digoxin, Simvastatin in Solid Tumors (NCT03889795) | Danae Hamouda, MD | 2019-06-05 |
| ORIN1001 in Patients with Advanced Solid Tumors and Relapsed Refractory Metastatic Breast Cancer (NCT03950570) | Orinove, Inc. | 2019-05-25 |
| Safety, Dose Tolerance, Pharmacokinetics, and Pharmacodynamics Study of CPX-POM in Patients With Advanced Solid Tumors (NCT04608045) | CicloMed LLC | 2019-05-19 |
| Gut Microbial Metabolites Inosine Combined With PD-1/PD-L1 Inhibitor for Patients With Malignant Advanced Solid Tumors (NCT05809336) | Beijing Friendship Hospital | 2019-05-01 |
| A Study of SHR-1702 Alone or With Camrelizumab in Participants With Advanced Relapsed/Refractory Solid Tumors (NCT03871855) | Jiangsu HengRui Medicine Co., Ltd. | 2019-04-28 |
| : A Phase Ib/II Study To Evaluate Fruquintinib Monotherapy Or Plus Sintilimab In Advanced Solid Tumors (NCT03903705) | Hutchmed | 2019-04-25 |
| Clinical Study on the Second-line and Above Treatment of Advanced Solid Tumor With Anlotinib Combined With Pd-1 Antibody (NCT03975036) | Henan Cancer Hospital | 2019-04-08 |
| Chimeric Antigen Receptor T Cells Targeting claudin18.2 in Solid Tumors. (NCT03874897) | Peking University | 2019-03-26 |
| Evaluation of Bibliotherapy by Students and Patients With Cancer (NCT03969082) | University Hospital, Ghent | 2019-03-09 |
| A Study of CBP-1008 in Patients With Advanced Solid Tumor (NCT04740398) | Coherent Biopharma (Suzhou) Co., Ltd. | 2019-03-06 |
| A Study of SHR-A1403 in Patients With Advanced Solid Tumor (NCT03856541) | Jiangsu HengRui Medicine Co., Ltd. | 2019-02-13 |
| First in Human Study of IBI101 in Chinese Subjects With Advanced Solid Tumors (NCT03758001) | Innovent Biologics (Suzhou) Co. Ltd. | 2019-02-13 |
| A Modular Multi-Basket Trial to Improve Personalized Medicine in Cancer Patients (Basket of Baskets) (NCT03767075) | Vall d'Hebron Institute of Oncology | 2018-12-10 |
| A Study to Evaluate the Tolerance and Pharmacokinetics of TQB3474 Injection (NCT04144855) | Chia Tai Tianqing Pharmaceutical Group Co., Ltd. | 2018-11-27 |
| A Study of MRG002 in the Treatment of Patients With HER2-positive Advanced Solid Tumors (NCT04941339) | Shanghai Miracogen Inc. | 2018-11-21 |
| Study of Dosage Exploration and Pharmacokinetics for HA121-28 Tablets (NCT03994484) | CSPC ZhongQi Pharmaceutical Technology Co., Ltd. | 2018-10-10 |
| Phase 1 Study of BAY1905254 - An Early Clinical Research Study to Evaluate a New Drug Called Bapotulimab (BAY1905254) in the Expansion Cohort in Combination With Pembrolizumab in Head and Neck Cancer That Has Returned or is Discovered to be Metastatic and is Expressing PDL1. (NCT03666273) | Bayer | 2018-09-12 |
| A Study of MSB2311 in Advanced Solid Tumors (NCT04272944) | Suzhou Transcenta Therapeutics Co., Ltd. | 2018-08-13 |
| PD-1 Antibody Expressing mesoCAR-T Cells for Mesothelin Positive Advanced Solid Tumor (NCT03615313) | Shanghai Cell Therapy Research Institute | 2018-08-06 |
| SyB C-0501(Oral Bendamustine) in Patients With Advanced Solid Tumors (NCT03604679) | SymBio Pharmaceuticals | 2018-05-24 |
| Phase I/II Study of Immunotherapy Combination BN-Brachyury Vaccine, M7824, N-803 and Epacadostat (QuEST1) (NCT03493945) | National Cancer Institute (NCI) | 2018-05-01 |
| Pembrolizumab (Anti-PD-1) and AMG386 (Angiopoietin-2 (Ang-2) in Patients With Advanced Solid Tumor (NCT03239145) | Dana-Farber Cancer Institute | 2018-05-01 |
| Tumor Immunotherapy and Microbiome Analysis (NCT04579978) | Sunnybrook Health Sciences Centre | 2018-04-01 |
| A Study of Rucaparib in Japanese Patients With a Previously-treated Solid Tumor (NCT03499444) | pharmaand GmbH | 2018-02-06 |
| A Phase I Study of SCC244 in Patients with Advanced MET Alterations Solid Tumors (NCT03457532) | Haihe Biopharma Co., Ltd. | 2017-12-16 |
| Evaluate the Effect of Entrectinib on the Pharmacokinetics of Midazolam in Cancer Patients (NCT03330990) | Hoffmann-La Roche | 2017-11-14 |
| Phase I Clinical Trial in Chinese Patients of Advanced and (or) Recurrent Solid Tumor/Lymphoma (NCT03374007) | Genor Biopharma Co., Ltd. | 2017-10-19 |
| Phase 1 Study of IM156 in Patients With Advanced Solid Tumor and Lymphoma (NCT03272256) | ImmunoMet Therapeutics, Inc. | 2017-10-09 |
| Special Combination of OBP-301 and Pembrolizumab (NCT03172819) | Toshihiko Doi | 2017-10-01 |
| Study to Evaluate the Safety and Anti-tumor Activity of SCC244 (NCT03466268) | Haihe Biopharma Co., Ltd. | 2017-09-14 |
| PM14 Administered Intravenously to Patients With Advanced Solid Tumors (NCT05076396) | PharmaMar | 2017-09-06 |
| Study to Evaluate the Safety, Preliminary Efficacy and Pharmacokinetics of 3810 (NCT03260179) | Haihe Biopharma Co., Ltd. | 2017-08-31 |
| Evaluation of the Safety and Tolerability of TAK-228 With TAK-117 and Paclitaxel in Advanced Solid Tumors (NCT03154294) | Avera McKennan Hospital & University Health Center | 2017-07-06 |
| First-in-human Study of ATR Inhibitor BAY1895344 in Patients With Advanced Solid Tumors and Lymphomas (NCT03188965) | Bayer | 2017-07-06 |
| Evaluation of the Added Value of a Large Molecular Profiling Panel Versus a Limited Molecular Profiling Panel in Advanced Solid Tumors. (NCT03163732) | Centre Leon Berard | 2017-06-29 |